SK283800B6 - Heptapeptidový analóg, farmaceutická kompozícia obsahujúca tento analóg, spôsob prípravy heptapeptidového analógu a jeho použitie pri príprave liečiva na redukciu alebo blokovanie kontrakcie maternicového svalu - Google Patents

Heptapeptidový analóg, farmaceutická kompozícia obsahujúca tento analóg, spôsob prípravy heptapeptidového analógu a jeho použitie pri príprave liečiva na redukciu alebo blokovanie kontrakcie maternicového svalu Download PDF

Info

Publication number
SK283800B6
SK283800B6 SK704-99A SK70499A SK283800B6 SK 283800 B6 SK283800 B6 SK 283800B6 SK 70499 A SK70499 A SK 70499A SK 283800 B6 SK283800 B6 SK 283800B6
Authority
SK
Slovakia
Prior art keywords
abu
asn
ile
mpa
trp
Prior art date
Application number
SK704-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK70499A3 (en
Inventor
Per Melin
Anders Nilsson
Jerzy Trojnar
Carl-Johan Aurell
Pierre Riviere
Robert Haigh
Original Assignee
Ferring B. V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring B. V. filed Critical Ferring B. V.
Publication of SK70499A3 publication Critical patent/SK70499A3/sk
Publication of SK283800B6 publication Critical patent/SK283800B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SK704-99A 1996-11-26 1997-11-21 Heptapeptidový analóg, farmaceutická kompozícia obsahujúca tento analóg, spôsob prípravy heptapeptidového analógu a jeho použitie pri príprave liečiva na redukciu alebo blokovanie kontrakcie maternicového svalu SK283800B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9604341A SE9604341D0 (sv) 1996-11-26 1996-11-26 Hepta-peptide oxytocin analogue
PCT/SE1997/001968 WO1998023636A1 (en) 1996-11-26 1997-11-21 Heptapeptide oxytocin analogues

Publications (2)

Publication Number Publication Date
SK70499A3 SK70499A3 (en) 2000-10-09
SK283800B6 true SK283800B6 (sk) 2004-02-03

Family

ID=20404757

Family Applications (1)

Application Number Title Priority Date Filing Date
SK704-99A SK283800B6 (sk) 1996-11-26 1997-11-21 Heptapeptidový analóg, farmaceutická kompozícia obsahujúca tento analóg, spôsob prípravy heptapeptidového analógu a jeho použitie pri príprave liečiva na redukciu alebo blokovanie kontrakcie maternicového svalu

Country Status (35)

Country Link
US (1) US6143722A (zh)
EP (1) EP0938496B1 (zh)
JP (1) JP3405460B2 (zh)
KR (1) KR100463132B1 (zh)
CN (1) CN1129606C (zh)
AR (1) AR008531A1 (zh)
AT (1) ATE242264T1 (zh)
AU (1) AU713424B2 (zh)
BR (1) BR9713366B1 (zh)
CA (1) CA2272990C (zh)
CZ (1) CZ299532B6 (zh)
DE (1) DE69722651T2 (zh)
DK (1) DK0938496T3 (zh)
EE (1) EE03832B1 (zh)
ES (1) ES2203823T3 (zh)
HK (1) HK1022481A1 (zh)
HR (1) HRP970630B1 (zh)
HU (1) HU228568B1 (zh)
IL (1) IL129519A (zh)
LT (1) LT4650B (zh)
LV (1) LV12350B (zh)
MY (1) MY125555A (zh)
NO (1) NO321380B1 (zh)
NZ (1) NZ336445A (zh)
PL (1) PL189292B1 (zh)
PT (1) PT938496E (zh)
RO (1) RO120772B1 (zh)
RU (1) RU2180668C2 (zh)
SE (1) SE9604341D0 (zh)
SI (1) SI20026B (zh)
SK (1) SK283800B6 (zh)
TR (1) TR199901028T2 (zh)
UA (1) UA54459C2 (zh)
WO (1) WO1998023636A1 (zh)
ZA (1) ZA9710518B (zh)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
US6476072B1 (en) * 2000-11-21 2002-11-05 Arthur Vanmoor Method of treating menstrual pain by enhancing the effectiveness of the human immune system
ES2277640T3 (es) * 2002-02-27 2007-07-16 Ferring Bv Productos intermedios y metodos para preparar analogos de heptapeptido de oxitocina.
US20060014147A1 (en) * 2002-05-02 2006-01-19 Stefan Golz Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
PT1530967E (pt) * 2003-11-13 2006-09-29 Ferring Bv Embalagem blister e uma forma de dosagem solida que compreende desmopressina.
EP1555029A1 (en) 2004-01-19 2005-07-20 Ferring B.V. Use of substances having oxytocin antagonistic properties for the preparation of a medicament for treating hypertension
US20060171909A1 (en) * 2005-02-03 2006-08-03 The Procter & Gamble Company Cosmetic compositions comprising colorants with low free dye
SE0600482L (sv) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
JP5451613B2 (ja) 2007-08-06 2014-03-26 アラーガン、インコーポレイテッド デスモプレシン薬物送達のための方法及びデバイス
PT2260053E (pt) * 2008-03-31 2014-08-29 Ferring Bv Análogos de oxitocina
ES2710454T3 (es) 2008-05-21 2019-04-25 Ferring Bv Desmopresina bucodispersable para aumentar el periodo inicial de sueño ininterrumpido por nocturia
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
TWI463990B (zh) * 2009-09-21 2014-12-11 Ferring Bv 催產素受體促進劑
AU2011278038B2 (en) 2010-07-15 2017-02-02 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
JO3400B1 (ar) * 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
WO2012121057A1 (ja) 2011-03-09 2012-09-13 Jitsubo株式会社 新規な非ペプチド性架橋構造を含む架橋ペプチド、ならびに該架橋ペプチドの合成方法および該方法に用いる新規な有機化合物
CN102875650B (zh) * 2012-09-26 2014-06-11 深圳翰宇药业股份有限公司 巴卢西班的制备方法
US9365615B2 (en) 2013-09-09 2016-06-14 Jitsubo Co., Ltd. Cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method
ES2716862T3 (es) * 2014-12-22 2019-06-17 Ferring Bv Terapia con antagonistas del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
KR20180059549A (ko) 2015-10-06 2018-06-04 훼링 비.브이. 바루시반 및 이의 중간체의 새로운 제조 방법
JP6933322B2 (ja) 2016-01-04 2021-09-08 メルク セローノ エス．エー． ヒドロキシプロピルチアゾリジンカルボキサミド誘導体のｌ−バリネート及びその塩形態、結晶多形
CA3031252A1 (en) 2016-07-21 2018-01-25 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
WO2021043726A1 (en) 2019-09-03 2021-03-11 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
US20230102503A1 (en) 2020-02-10 2023-03-30 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2036973A1 (en) * 1990-02-27 1991-08-28 Mark G. Bock Cyclic hexapeptide oxytocin antagonists
SE9002384D0 (sv) * 1990-07-09 1990-07-09 Ferring Ab Derivat av baklobshormoner
SE501678C2 (sv) * 1993-07-13 1995-04-10 Ferring Bv Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid
SE523819C2 (sv) 1994-01-27 2004-05-18 Per-Ingvar Nilsson Accelerationsmunstycke samt metod för dess användning
SE9400918L (sv) 1994-03-18 1995-09-19 Anne Fjellstad Paulsen Stabiliserad komposition för oral administrering av peptider
SE9500249L (sv) 1995-01-25 1996-03-25 Valeo Engine Cooling Ab Värmeväxlartank med ändstycken, förfarande för framställning av en sådan tank, samt värmeväxlare försedd med en sådan

Also Published As

Publication number Publication date
DK0938496T3 (da) 2003-10-06
EE9900210A (et) 1999-12-15
UA54459C2 (uk) 2003-03-17
JP2000507617A (ja) 2000-06-20
LT99052A (en) 2000-01-25
LT4650B (lt) 2000-04-25
HRP970630A2 (en) 1998-10-31
AU5142998A (en) 1998-06-22
CN1238781A (zh) 1999-12-15
JP3405460B2 (ja) 2003-05-12
MY125555A (en) 2006-08-30
CA2272990C (en) 2002-11-19
NZ336445A (en) 2000-06-23
DE69722651T2 (de) 2004-04-08
EP0938496B1 (en) 2003-06-04
US6143722A (en) 2000-11-07
SE9604341D0 (sv) 1996-11-26
LV12350A (lv) 1999-09-20
RO120772B1 (ro) 2006-07-28
ES2203823T3 (es) 2004-04-16
BR9713366A (pt) 2000-01-25
CZ299532B6 (cs) 2008-08-27
ATE242264T1 (de) 2003-06-15
ZA9710518B (en) 1998-06-10
KR100463132B1 (ko) 2004-12-23
IL129519A (en) 2004-09-27
CZ183299A3 (cs) 2000-05-17
AU713424B2 (en) 1999-12-02
CN1129606C (zh) 2003-12-03
KR20000069045A (ko) 2000-11-25
PL189292B1 (pl) 2005-07-29
EP0938496A1 (en) 1999-09-01
NO321380B1 (no) 2006-05-02
EE03832B1 (et) 2002-08-15
AR008531A1 (es) 2000-01-19
TR199901028T2 (xx) 1999-07-21
WO1998023636A1 (en) 1998-06-04
SK70499A3 (en) 2000-10-09
IL129519A0 (en) 2000-02-29
SI20026A (sl) 2000-02-29
HU228568B1 (en) 2013-04-29
SI20026B (sl) 2000-06-30
BR9713366B1 (pt) 2010-05-18
HRP970630B1 (en) 2002-04-30
HUP0000577A3 (en) 2001-02-28
RU2180668C2 (ru) 2002-03-20
PT938496E (pt) 2003-10-31
NO992532D0 (no) 1999-05-26
DE69722651D1 (en) 2003-07-10
CA2272990A1 (en) 1998-06-04
HK1022481A1 (en) 2000-08-11
HUP0000577A2 (hu) 2000-11-28
LV12350B (en) 1999-11-20
NO992532L (no) 1999-05-26

Similar Documents

Publication Publication Date Title
SK283800B6 (sk) Heptapeptidový analóg, farmaceutická kompozícia obsahujúca tento analóg, spôsob prípravy heptapeptidového analógu a jeho použitie pri príprave liečiva na redukciu alebo blokovanie kontrakcie maternicového svalu
FI92326C (fi) LHRH:n nonapeptidi- ja dekapeptidianalogeja, jotka ovat käyttökelpoisia LHRH:n antagonisteina
SK285381B6 (sk) Peptid antagonistický k hormónu uvoľňujúcemu gonadotropín (GnRH), farmaceutický prostriedok s jeho obsahom, jeho použitie a medziprodukt
JP3838656B2 (ja) ポリペプチドのボンベシン拮抗物質
US4604378A (en) Basic V1 -vasopressin antagonists
CA2022740C (en) Cyclic neurokinin a antagonists
US4684621A (en) Methods of producing vasodilation or antioxytocic activity
AU8225191A (en) Derivatives of pituitary posterior lobe hormones
US4658015A (en) Polypeptide intermediates
US6218364B1 (en) Fluorinated neurokinin A antagonists
TW386086B (en) Heptapeptide oxytocin analogues
IE902136L (en) Irreversible bombesin antagonists.
JPS63303999A (ja) バソプレシン拮抗剤
Callahan et al. Basic V 1-vasopressin antagonists
CZ993A3 (en) derivatives of neurohypophysis lobe hormones

Legal Events

Date Code Title Description
MK4A Expiry of patent

Expiry date: 20171121